Cirrhosis and End Stage Liver Disease: complications and management of conditions such as portal hypertension, ascites and encephalopathy.

· Cirrhosis and end-Stage Liver Disease

o Ascites

§ 676. Renal failure and bacterial infection in patients with cirrhosis and ascites: relationship with the type and the resolution of the infection (updated October 29, 2006)

o Encephalopathy

§ 711. Hepatic Encephalopathy Predicting Survival

§ 751. Anxiety and Depressive Symptoms in Patients with Resolving Hepatic Encephalopathy (updated October 30, 2006)

o General

§ 216. Impact of caffeine consumption on histological activity in patients with Chronic Active Hepatitis C

§ 713. Loss of muscular mass is an independent factor associated with mortality in liver cirrhosis: prospective analysis of 206 patients (updated October 29, 2006)

§ 715. Renal dysfunction is associated with cognitive impairment in patients with liver cirrhosis (updated October 29, 2006)

§ 733. Quality of Care for Ambulatory Patients with Cirrhosis in an Academic Medical Center (updated October 29, 2006)

§ 734. Health-Related Quality of Life among Patients with Cirrhosis in the United States (updated October 30, 2006)

§ 741. Clinical and biochemical effect of G-CSF administration in patients with acute on chronic liver failure

§ 742. A late evening snack combined with α-glucosidase inhibitor administration: Effects on liver cirrhosis

§ 1135. Tumor ablation plus interferon therapy can reduce the risk of death for patients with hepatitis B virus or hepatitis C virus-related resectable hepatocellular carcinoma - A meta-analysis of randomized controlled trials

o Portal Hypertension

§ 675. Cost-effectiveness of distal splenorenal shunt (DSRS) vs. transjugular intrahepatic portosystemic shunt (TIPS) (updated October 29, 2006)

§ 688. Thrombophilia-associated nodular regenerative hyperplasia: a new cause of non-cirrhotic portal hypertension in HIV-infected patients

§ 719. The effect of antiviral therapy on clinical outcome of HCV cirrhosis with portal hypertension: a prospective cohort study

§ 737. Hospitalization Rates for Complications of Cirrhosis and Portal Hypertension Have Increased Significantly in the USA Between 1998 and 2003

o Varices

§ 682. Primary Prophylaxis of Variceal Hemorrhage – Patient Preferences (updated October 29, 2006)

§ 684. Predicting patient survival in compensated cirrhotics with refractory variceal bleeding treated with distal splenorenal (DSRS) or transjugular intrahepatic portosystemic (TIPS) shunts (updated October 29, 2006)

§ 708. Updated long-term outcome after variceal bleeding using currently available treatments to prevent rebleeding (updated October 29, 2006)

§ 718. Variceal band ligation versus beta blockers for primary prevention of variceal bleeding: An updated meta-analysis (updated October 29, 2006)

§ 721. Platelet count as a non-invasive predictor of esophageal varices

§ 728. Nationwide Trends in the Incidence of Bleeding and Non-Bleeding Esophageal Varices in Hospitalized Patients in the United States (updated October 29, 2006)

§ 739. Primary prophylaxis with band ligation is safe and effective in patients with contraindications, intolerance or non responding to beta-blockers: a pragmatic study

§ 753. Clinical Features of Upper Gastrointestinal Bleeding in Patients with Cirrhosis: A Multicenter Cohort Study